Bayer (BAYRY) announced that its wholly owned and independently operating subsidiary, Asklepios BioPharmaceutical, Inc. (AskBio), initiated recruitment in the mid-stage study REGENERATE-PD.REGENERATE-PD is a phase II study evaluating the efficacy and safety of AB-1005, an investigational adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease.Subjects will receive either bilateral image-guided infusion of AAV2-GD ...